Diabetes, Obesity and Metabolism
Издатель: Wiley · ISSN 14628902 · 81 статей
-
Exploring Corresponding Cutpoints for Hypoglycaemia Awareness Questionnaire (HypoA‐Q) Impaired Awareness Subscale in Relation to the Gold and Clarke Measures: A Post Hoc Analysis From the Hypo‐METRICS Study
ABSTRACT Aims The Hypoglycaemia Awareness Questionnaire–Impaired Awareness subscale (HypoA‐Q/IA) was developed to enhance impaired awareness of hypoglycaemia (IAH) assessment, addressing methodological deficiencies of the established...
- Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies
- Correction to ‘Gold and Clarke Questionnaires Identify Different People With Insulin‐Treated Diabetes and Impaired Awareness of Hypoglycaemia in Almost 60% of Cases: A Post Hoc Analysis From the Hypo‐METRICS Study’
-
Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation
ABSTRACT Aims To compare the risk of incident alcohol use disorder (AUD) among adults with Type 2 diabetes (T2D) initiating semaglutide, tirzepatide or sodium‐glucose cotransporter‐2 inhibitors (SGLT2i). Materials and Methods We...
-
Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS‐HF
ABSTRACT Background Finerenone reduces the risk of heart failure and cardiovascular (CV) death among patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether the effects of finerenone to...
-
Closed‐Loop Insulin Delivery in Inpatient Care: A Systematic Review and Meta‐Analysis of Clinical and Implementation Outcomes
ABSTRACT Aims Closed‐loop (CL) insulin delivery systems have transformed outpatient diabetes care. However, evidence supporting their role in inpatient settings is limited. This systematic review and meta‐analysis evaluated the safety,...
-
Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis
ABSTRACT Background and Aims Compensated MASH cirrhosis is an advanced disease with no current approved pharmacologic therapy. FGF analogues have shown biological activity, but individual trials have not established histologic efficacy....
- Prevalence of Chronic Complications After Inaugural Admission in Intensive Care Unit for Type 1 Diabetes in the SFDT1 Cohort: The INAUGURAL Study
- Accuracy and Safety of the LinX Continuous Glucose Monitoring System in Adults With Diabetes: A Prospective Multicentre Open‐Label Clinical Performance Study
- Potential Associations Between GLP‐1 Receptor Agonists and Polyendocrine Metabolic Ovarian Syndrome: Triangulation of Genetic and Pharmacovigilance Evidence
- Urban Burden Index–Multidomain Assessment of Integrated Obesogenic Risk (UBI‐MAIOR) and Obesity Prevalence Across 10 Metropolitan Areas: An Exploratory Pilot Analysis
- Glucagon‐Like Peptide‐1 Medicines and Risk of Dysaesthesia: A Systematic Review, Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials
- Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes
- Trends in GLP‐1‐Based Therapy Use Before and After Pregnancy
- Pre‐Bedtime Whey Protein Ingestion Increases Blood Glucose Overnight in Adults With Type 1 Diabetes
- Beyond Weight Loss: The Challenge of Stopping Obesity Management Medications
- A Multicentre Study of Prevalence and Risk Factors of Diabetic Retinopathy in Children and Young People With Type 1 Diabetes in the United Kingdom
- Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD
- Distinguishing Biology From Clinical Surveillance in Postpartum Biomarker Trajectories After Gestational Diabetes
- Weight Loss Is Not Surgical Readiness: The Missing Operative Phenotype in GLP‐1 Body‐Composition Assessment
- Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies